To determine the potential molecular mechanism governing the ability of YBX1 to inhibit the sensitivity to cisplatin of NSCLC cells, we added the cisplatin in NSCLC cells after transfect YBX1 siRNA and Bcl-2 siRNA. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.